blank Quick help
blank Maintenance news

Misleading Register Alert event notification on 15.04.19

Following a clean-up exercise of event information regarding (previously) revoked patents, that were later reinstated, some existing revocation events ("Despatch of communication that patent is revoked") were duplicated on 15.04.2019.

2019.04.15

More...
blank News flashes

European Patent Register Assistant updated

In order to offer you the best possible learning experience we have launched an updated version of the European Patent Register Assistant online tutorial to include recent changes in the Register.

2019.08.29

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

About this file: EP2007809

EP2007809 - GLYCOSYLATED ANTIBODIES [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  10.08.2018
Database last updated on 21.09.2019
Most recent event   Tooltip10.08.2018Patent maintained (B2 publication)published on 12.09.2018  [2018/37]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstraße 124
4070 Basel / CH
[2018/37]
Former [2009/01]For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Inventor(s)01 / HANSEN, Silke
Egerlaender Strasse 3
82393 Iffeldorf / DE
02 / KUENKELE, Klaus-Peter
Karwendelstrasse 9
83671 Benediktbeuern / DE
03 / REUSCH, Dietmar
Tessiner Strasse 113
81475 München / DE
04 / SCHUMACHER, Ralf
Hochfeldstrasse 78
82377 Penzberg / DE
 [2009/01]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2018/37]
Former [2013/37]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Former [2009/01]Burger, Alexander , et al
Roche Diagnostics GmbH Patent Department (TR-E) Postfach 11 52
82372 Penzberg / DE
Former [2008/43]Burger, Alexander , et al
Roche Diagnostics GmbH,Patent Department (TR-E), Postfach 1152
82372 Penzberg / DE
Application number, filing date07724105.710.04.2007
[2009/01]
WO2007EP03164
Priority number, dateEP2006000756511.04.2006         Original published format: EP 06007565
EP2006001620303.08.2006         Original published format: EP 06016203
[2009/01]
Filing languageEN
Procedural languageEN
PublicationType: A1  Application with search report
No.:WO2007115813
Date:18.10.2007
Language:EN
[2007/42]
Type: A1 Application with search report 
No.:EP2007809
Date:31.12.2008
Language:EN
The application has been published by WIPO in one of the EPO official languages on 18.10.2007
[2009/01]
Type: B1 Patent specification 
No.:EP2007809
Date:12.09.2012
Language:EN
[2012/37]
Type: B2 New European patent specification 
No.:EP2007809
Date:12.09.2018
Language:EN
[2018/37]
Search report(s)International search report - published on:EP18.10.2007
ClassificationInternational:C07K16/28, C12P21/00, A61K39/395, A61P35/00, A61P37/00, C07K16/00
[2009/01]
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/37]
Former [2009/01]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesHR11.11.2008
RS11.11.2008
TitleGerman:GLYKOSYLIERTE ANTIKÖRPER[2009/01]
English:GLYCOSYLATED ANTIBODIES[2009/01]
French:ANTICORPS GLYCOSYLÉS[2009/01]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase11.11.2008National basic fee paid 
11.11.2008Designation fee(s) paid 
11.11.2008Examination fee paid 
Examination procedure06.02.2008Request for preliminary examination filed
International Preliminary Examining Authority: EP
11.11.2008Examination requested  [2009/01]
09.02.2009Despatch of a communication from the examining division (Time limit: M06)
23.09.2009Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
23.11.2009Reply to a communication from the examining division
08.12.2009Despatch of a communication from the examining division (Time limit: M06)
15.06.2010Reply to a communication from the examining division
23.06.2010Despatch of a communication from the examining division (Time limit: M04)
06.10.2010Reply to a communication from the examining division
14.10.2010Despatch of a communication from the examining division (Time limit: M06)
13.04.2011Reply to a communication from the examining division
27.02.2012Communication of intention to grant the patent
22.06.2012Fee for grant paid
22.06.2012Fee for publishing/printing paid
Divisional application(s)EP10166861.4  / EP2248831
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.02.2009
Opposition(s)Opponent(s)01  12.06.2013  22.06.2017  WITHDRAWN
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Carpmaels & Ransford LLP, et al
One Southampton Row
London WC1B 5HA / GB
 02  12.06.2013  17.06.2013  ADMISSIBLE
Glaxo Group Limited
980 Great West Road
Brentford Middlesex TW8 9GS / GB
Opponent's representative
Bhogal, Jasber Kaur, et al
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
 [2018/30]
Former [2016/52]
Opponent(s)01  12.06.2013  18.06.2013  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Carpmaels & Ransford LLP, et al
One Southampton Row
London WC1B 5HA / GB
 02  12.06.2013  17.06.2013  ADMISSIBLE
Glaxo Group Limited
980 Great West Road
Brentford Middlesex TW8 9GS / GB
Opponent's representative
Bhogal, Jasber Kaur, et al
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Former [2016/08]
Opponent(s)01  12.06.2013  18.06.2013  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Cabinet Plasseraud, et al
66, rue de la Chaussée d'Antin
75440 Paris Cedex 09 / FR
 02  12.06.2013  17.06.2013  ADMISSIBLE
Glaxo Group Limited
980 Great West Road
Brentford Middlesex TW8 9GS / GB
Opponent's representative
Bhogal, Jasber Kaur, et al
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Former [2013/30]
Opponent(s)01  12.06.2013  18.06.2013  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Cabinet Plasseraud, et al
235 Cours Lafayette
69006 Lyon / FR
 02  12.06.2013  17.06.2013  ADMISSIBLE
Glaxo Group Limited
980 Great West Road
Brentford Middlesex TW8 9GS / GB
Opponent's representative
Bhogal, Jasber Kaur, et al
GlaxoSmithKline
Global Patents CN925.1
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Former [2013/29]
Opponent(s)01  12.06.2013   
Novartis AG
Lichtstrasse 35
4065 Basel / CH
 02  12.06.2013   
Glaxo Group Limited
980 Great West Road
Brentford Middlesex TW8 9GS / GB
Opponent's representative
Bhogal, Jasber Kaur, et al
GlaxoSmithKline
Global Patents CN925.1
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
08.07.2013Invitation to proprietor to file observations on the notice of opposition
20.01.2014Reply of patent proprietor to notice(s) of opposition
16.06.2015Date of oral proceedings
13.07.2015Despatch of interlocutory decision in opposition
13.07.2015Despatch of minutes of oral proceedings
22.06.2017Legal effect of interlocutory decision in opposition
30.07.2018Despatch of communication that the patent will be maintained as amended
31.07.2018Fee for printing new specification paid
Appeal following opposition14.09.2015Appeal received No.  T1784/15
23.11.2015Statement of grounds filed
22.06.2017Result of appeal procedure: appeal of the opponent was rejected
10.09.2015Appeal received No.  T1784/15
13.11.2015Statement of grounds filed
15.04.2016Invitation to file observations in an appeal (Time limit: M04) [2016/16]
25.08.2016Date of receipt of observations in an appeal [2016/35]
22.06.2017Result of appeal procedure: appeal of the opponent was rejected
22.06.2017Date of oral proceedings
26.06.2017Minutes of the oral proceedings despatched
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
23.11.2009Request for further processing filed
23.11.2009Full payment received (date of receipt of payment)
Fees paidRenewal fee
07.04.2009Renewal fee patent year 03
15.03.2010Renewal fee patent year 04
06.04.2011Renewal fee patent year 05
21.03.2012Renewal fee patent year 06
Lapses during opposition  TooltipHU10.04.2007
AT12.09.2012
BE12.09.2012
CY12.09.2012
CZ12.09.2012
DK12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
MC12.09.2012
MT12.09.2012
NL12.09.2012
PL12.09.2012
RO12.09.2012
SE12.09.2012
SI12.09.2012
SK12.09.2012
BG12.12.2012
GR13.12.2012
IS12.01.2013
PT14.01.2013
IE10.04.2013
LU10.04.2013
[2015/34]
Former [2015/13]AT12.09.2012
BE12.09.2012
CY12.09.2012
CZ12.09.2012
DK12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
MC12.09.2012
MT12.09.2012
NL12.09.2012
PL12.09.2012
RO12.09.2012
SE12.09.2012
SI12.09.2012
SK12.09.2012
BG12.12.2012
GR13.12.2012
IS12.01.2013
PT14.01.2013
IE10.04.2013
Former [2014/20]AT12.09.2012
BE12.09.2012
CY12.09.2012
CZ12.09.2012
DK12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
MC12.09.2012
NL12.09.2012
PL12.09.2012
RO12.09.2012
SE12.09.2012
SI12.09.2012
SK12.09.2012
BG12.12.2012
GR13.12.2012
IS12.01.2013
PT14.01.2013
IE10.04.2013
Former [2014/01]AT12.09.2012
BE12.09.2012
CY12.09.2012
CZ12.09.2012
DK12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
MC12.09.2012
NL12.09.2012
PL12.09.2012
RO12.09.2012
SE12.09.2012
SI12.09.2012
SK12.09.2012
BG12.12.2012
GR13.12.2012
IS12.01.2013
PT14.01.2013
Former [2013/34]AT12.09.2012
BE12.09.2012
CY12.09.2012
CZ12.09.2012
DK12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
NL12.09.2012
PL12.09.2012
RO12.09.2012
SE12.09.2012
SI12.09.2012
SK12.09.2012
BG12.12.2012
GR13.12.2012
IS12.01.2013
PT14.01.2013
Former [2013/31]AT12.09.2012
BE12.09.2012
CY12.09.2012
CZ12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
NL12.09.2012
PL12.09.2012
RO12.09.2012
SE12.09.2012
SI12.09.2012
SK12.09.2012
GR13.12.2012
IS12.01.2013
PT14.01.2013
Former [2013/28]BE12.09.2012
CY12.09.2012
CZ12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
NL12.09.2012
PL12.09.2012
RO12.09.2012
SE12.09.2012
SI12.09.2012
SK12.09.2012
GR13.12.2012
IS12.01.2013
PT14.01.2013
Former [2013/23]BE12.09.2012
CY12.09.2012
CZ12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
NL12.09.2012
PL12.09.2012
RO12.09.2012
SE12.09.2012
SI12.09.2012
SK12.09.2012
GR13.12.2012
IS12.01.2013
Former [2013/22]BE12.09.2012
CY12.09.2012
CZ12.09.2012
EE12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
NL12.09.2012
SE12.09.2012
SI12.09.2012
GR13.12.2012
IS12.01.2013
Former [2013/20]BE12.09.2012
CY12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
SE12.09.2012
SI12.09.2012
GR13.12.2012
Former [2013/12]CY12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
SE12.09.2012
SI12.09.2012
GR13.12.2012
Former [2013/11]CY12.09.2012
FI12.09.2012
LT12.09.2012
LV12.09.2012
SI12.09.2012
GR13.12.2012
Former [2013/10]CY12.09.2012
FI12.09.2012
LT12.09.2012
Former [2013/09]FI12.09.2012
LT12.09.2012
Former [2013/08]LT12.09.2012
Cited inInternational search[Y]US2005024972  (SCHAEFER SCOTT [US]) [Y] 1-14 * page 14 - page 15 * * tables 1,3 * * figures 8,9 *;
 [A]WO2005023872  (HOFFMANN LA ROCHE [CH], et al) [A] 1-14 * the whole document *;
 [DX]  - DAVIES J ET AL, "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII", BIOTECHNOLOGY AND BIOENGINEERING - COMBINATORIAL CHEMISTRY, WILEY, NEW YORK, NY, US, (20010820), vol. 74, no. 4, ISSN 0006-3592, pages 288 - 294, XP002285964 [DX] 1-6,9-14 * page 289 - page 290, column 1 * * page 291, column 2 * * figures 3A,4-6 * * table 1 *

DOI:   http://dx.doi.org/10.1002/bit.1119
 [DX]  - ROUTIER F H ET AL, "The glycosylation pattern of a humanized IgGI antibody (D1.3) expressed in CHO cells", GLYCOCONJUGATE JOURNAL, LUND, SE, (1997), vol. 14, no. 2, ISSN 0282-0080, pages 201 - 207, XP002375244 [DX] 1-6,13,14 * page 202 - page 203 * * page 205 - page 206 * * figures 3,4 * * table 2 *

DOI:   http://dx.doi.org/10.1023/A:1018589704981
 [DX]  - SHEELEY DOUGLAS M ET AL, "Characterization of monoclonal antibody glycosylation: Comparison of expression systems and identification of terminal alpha-linked galactose", ANALYTICAL BIOCHEMISTRY, (1997), vol. 247, no. 1, ISSN 0003-2697, pages 102 - 110, XP002385237 [DX] 1-6,13,14 * pages 104-107 * * page 108, column 2 * * figures 2,3,6 *

DOI:   http://dx.doi.org/10.1006/abio.1997.2036
 [DX]  - ZHU LEI ET AL, "Production of human monoclonal antibody in eggs of chimeric chickens", NATURE BIOTECHNOLOGY, (200509), vol. 23, no. 9, ISSN 1087-0156, pages 1159 - 1169, XP002385238 [DX] 1-5,9-11 * page 1163, column 1, paragraph 2 * * figure 3b * * table 2 *

DOI:   http://dx.doi.org/10.1038/nbt1132
 [DY]  - SHIELDS R L ET AL, "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (20020726), vol. 277, no. 30, ISSN 0021-9258, pages 26733 - 26740, XP002964542 [DY] 1-14 * page 26734, column 1 - column 2, paragraph 4 * * page 26734, column 2, paragraph 5 * * figures 1,6 * * table 1 *

DOI:   http://dx.doi.org/10.1074/jbc.M202069200
 [PA]  - SCHNITZER ET AL, "214 POSTER Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, (200611), vol. 4, no. 12, ISSN 1359-6349, pages 66 - 67, XP005810433 [PA] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1359-6349(06)70219-1
Examination   - ROUTIER ET AL, "Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods.", JOURNAL OF IMMUNOLOGICAL METHODS, (19980401), vol. 213, no. 2, ISSN 0022-1759, pages 113 - 130, XP055013177

DOI:   http://dx.doi.org/10.1016/S0022-1759(98)00032-5
by applicantWO2004087756
 WO2005005635
    - ROUTIER, F.H. ET AL., GLYCOCONJUGATE, (1997), vol. 14, pages 201 - 207
    - NIWA, R. ET AL., J. IMMUNOL. METHODS, (2005), vol. 306, pages 151 - 160
    - MIMURA, Y ET AL., J. IMMUNOL. METHODS, (2001), vol. 247, pages 205 - 216
    - RAJU, T.S., BIOPROCESS INTERNATIONAL, (2003), vol. 1, pages 44 - 53
    - MA, S., ANAL. CHEM., (1999), vol. 71, pages 5185 - 5192
    - FUJII, S., J. BIOL. CHEM., (1990), vol. 265, pages 6009 - 6018
    - MIZOUCHI, T., J. IMMUNOL., (1982), vol. 129, pages 2016 - 2020
    - BERGWERFF, A.A., GLYCOCONJUGATE J., (1995), vol. 12, pages 318 - 330
    - NAHRGANG, S. ET AL., Animal Cell Technology: Products from Cells, Cells as Products, KLUWER ACADEMIC PUBLISHERS, (1999), pages 259 - 261
    - LUND, J. ET AL., MOL. IMMUNOL., (1993), vol. 30, pages 741 - 748
    - PATEL, T.P. ET AL., BIOCHEM. J., (1992), vol. 285, pages 839 - 845
    - MORI, K. ET AL., BIOTECH. BIOENG., (2004), vol. 88, pages 901 - 908
    - DAVIES, J. ET AL., BIOTECHNOL. BIOENG., (2001), vol. 74, pages 288 - 294
    - SHEELEY, D.M. ET AL., ANAL. BIOCHEM., (1997), vol. 247, pages 102 - 110
    - SHIELDS, RL. ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 26733 - 26740
    - ZHU, L. ET AL., NATURE BIOTECHNOL., (2005), vol. 23, pages 1159 - 1169
OppositionWO2005040221
 WO2005115453
    - SHINKAWA T; ET AL, "THE ABSENCE OF FUCOSE BUT NOT THE PRESENCE OF GALACTOSE OR BISECTING N-ACETYLGLUCOSAMINE OF HUMAN IGG1 COMPLEX-TYPE OLIGOSACCHARIDES SHOWS THE CRITICAL ROLE OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY", JOURNAL OF BIOLOGICAL CHEMISTRY, (20030131), vol. 278, no. 5, pages 3466 - 3473, XP002965857

DOI:   http://dx.doi.org/10.1074/jbc.M210665200
    - SHAN CHUNG, ET AL, "QUANTITATIVE EVALUATION OF FUCOSE REDUCING EFFECTS IN A HUMANIZED ANTIBODY ON FC? RECEPTOR BINDING AND ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY ACTIVITIES", MABS, LANDES BIOSCIENCE, (20120501), vol. 4, no. 3, pages 326 - 340, XP055302095

DOI:   http://dx.doi.org/10.4161/mabs.19941
    - WAGNER-ROUSSET E, ET AL, "THE WAY FORWARD, ENHANCED CHARACTERIZATION OF THERAPEUTIC ANTIBODY GLYCOSYLATION: COMPARISON OF THREE LEVEL MASS SPECTROMETRY-BASED STRATEGIES", JOURNAL OF CHROMATOGRAPHY B, vol. 872, no. 1-2, pages 23 - 37, XP024098449

DOI:   http://dx.doi.org/10.1016/j.jchromb.2008.03.032
    - WURM, FLORIAN M., "PRODUCTION OF RECOMBINANT PROTEIN THERAPEUTICS IN CULTIVATED MAMMALIAN CELLS", NATURE BIOTECHNOLOGY, vol. 22, no. 11, pages 1393 - 1398, XP002667427

DOI:   http://dx.doi.org/DOI:10.1038/NBT1026
    - PALLAVICINI, M. ET AL, "EFFECTS OF METHOTREXATE ON TRANSFECTED DNA STABILITY IN MAMMALIAN CELLS", MOLECULAR AND CELLULAR BIOLOGY, (199001), vol. 10, no. 1, pages 401 - 404
    - GANDOR, C. ET AL, "AMPLIFICATION AND EXPRESSION OF RECOMBINANT GENES IN SERUM-INDEPENDENT CHINESE HAMSTER OVARY CELLS", FEBS LETTERS, vol. 377, no. 3, pages 290 - 294, XP026563654

DOI:   http://dx.doi.org/10.1016/0014-5793(95)01328-8
    - WURM, F. ET AL, "INDUCIBLE OVERPRODUCTION OF THE MOUSE C-MYC PROTEIN IN MAMMALIAN CELLS", PNAS, (198608), vol. 83, pages 5414 - 5418
    - DEROUAZI, M. ET AL, "GENETIC CHARACTERIZATION OF CHO PRODUCTION HOST DG44 AND DERIVATIVE RECOMBINANT CELL LINES", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 340, no. 4, pages 1069 - 1077, XP024924155

DOI:   http://dx.doi.org/10.1016/j.bbrc.2005.12.111
    - CHUSAINOW JANET; ET AL, "A STUDY OF MONOCLONAL ANTIBODY-PRODUCING CHO CELL LINES: WHAT MAKES A STABLE HIGH PRODUCER?", BIOTECHNOLOGY AND BIOENGINEERING, (20081008), vol. 102, no. 4, pages 1182 - 1196, XP002525682

DOI:   http://dx.doi.org/10.1002/BIT.22158
    - RAJU T S; ET AL, "SPECIES-SPECIFIC VARIATION IN GLYCOSYLATION OF IGG: EVIDENCE FOR SPECIES-SPECIFIC SIALYLATION AND BRANCH-SPECIFIC GALACTOSYLATION AND IMPORTANCE FOR ENGINEERING RECOMBINANT GLYCOPROTEIN THERAPEUTICS", GLYCOBIOLOGY, (20000101), vol. 10, no. 5, pages 477 - 486, XP002964086

DOI:   http://dx.doi.org/10.1093/glycob/10.5.477
    - JEFFERIS ROYSTON, "GLYCOSYLATION OF RECOMBINANT ANTIBODY THERAPEUTICS", BIOTECHNOLOGY PROGRESS, (20050101), vol. 21, no. 1, pages 11 - 16, XP002456627

DOI:   http://dx.doi.org/10.1021/bp040016j
    - JENKINS N; ET AL, "GETTING THE GLYCOSYLATION RIGHT: IMPLICATIONS FOR THE BIOTECHNOLOGY INDUSTRY", NATURE BIOTECHNOLOGY, (19960801), vol. 14, no. 8, pages 975 - 981, XP002133654

DOI:   http://dx.doi.org/10.1038/nbt0896-975
    - HOSSLER P, ET AL, "OPTIMAL AND CONSISTENT PROTEIN GLYCOSYLATION IN MAMMALIAN CELL CULTURE", GLYCOBIOLOGY, (20090901), vol. 19, no. 9, pages 936 - 949, XP055112498

DOI:   http://dx.doi.org/10.1093/glycob/cwp079
    - STADLMAN, J. ET AL, "ANALYSIS OF IMMUNOGLOBULIN GLYCOSYLATION BY LC-ESI-MS OF GLYCOPEPTIDES AND OLIGOSACCHARIDES", PROTEOMICS, (2008), vol. 8, doi:doi:10.1002/pmic.200700968, pages 2858 - 2871, XP055188198

DOI:   http://dx.doi.org/10.1002/pmic.200700968
    - HUANG L, ET AL, "IMPACT OF VARIABLE DOMAIN GLYCOSYLATION ON ANTIBODY CLEARANCE: AN LC/MS CHARACTERIZATION", ANALYTICAL BIOCHEMISTRY, (20060215), vol. 349, no. 2, pages 197 - 207, XP024941990

DOI:   http://dx.doi.org/10.1016/j.ab.2005.11.012
    - BECK, A. ET AL, "CHARACTERIZATION BY LIQUID CHROMATOGRAPHY COMBINED WITH MASS SPECTROMETRY OF MONOCLONAL ANTI-IGF-1 RECEPTOR ANTIBODIES PRODUCED IN CHO AND NS0 CELLS", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES, vol. 819, no. 2, pages 203 - 218, XP027627318
    - KING, J., "APPLICATIONS AND ENGINEERING OF MONOCLONAL ANTIBODIES", CRC PRESS, (1998), pages 54 - 55
    - CORBLEY, M., "PROTEIN THERAPEUTICS IN ONCOLOGY", SIGNALING PATHWAYS IN CANCER PATHOGENESIS AND THERAPY, SPRINGER, no. 7, page 138
    - WUHRER, M., "GLYCOMICS USING MASS SPECTROMETRY", GLYCOCONJ J, (2013), vol. 30, doi:doi:10.1007/s10719-012-9376-3, pages 11 - 22, XP035166114

DOI:   http://dx.doi.org/10.1007/s10719-012-9376-3
    - MATSUMIYA S. ET AL, "STRUCTURAL COMPARISON OF FUCOSYLATED AND NONFUCOSYLATED FC FRAGMENTS OF HUMAN IMMUNOGLOBULIN G1", JOURNAL OF MOLECULAR BIOLOGY, (20070504), vol. 368, no. 3, pages 767 - 779, XP002696786

DOI:   http://dx.doi.org/10.1016/j.jmb.2007.02.034
    - SHATZ, W. ET AL, "KNOBS-INTO-HOLES ANTIBODY PRODUCTION IN MAMMALIAN CELL LINES REVEALS THAT ASYMMETRIC AFUCOSYLATION IS SUFFICIENT FOR FULL ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY", MABS, (20131101), vol. 5, no. 6, pages 872 - 881, XP055282425

DOI:   http://dx.doi.org/10.4161/mabs.26307